Exact Sciences — Jul 31, 2024 release

Precision Oncology includes laboratory service revenue from global Oncotype DX and therapy selection tests. 2024 outlook The Company has maintained its full-year 2024 revenue guidance and raised its full-year 2024 adjusted EBITDA guidance: Prior guidance July 31 update Total revenue $2.810 - $2.850 billion $2.810 - $2.850 billion Screening $2.155 - $2.175 billion $2.155 - $2.175 billion Precision Oncology $655 - $675 million $655 - $675 million Adjusted EBITDA $325 - $350 million $335 - $355 million Second-quarter 2024 conference call & webcast Company management will host a conference call and webcast on Wednesday, July 31, 2024, at 5 p.m. ET to discuss second-quarter 2024 results. The webcast will be available at exactsciences.com. Domestic callers should dial 888-330-2384 and international callers should dial +1-240-789-2701. The access code for both domestic and international callers is 4437608. A replay of the webcast will be available at exactsciences.com. The webcast, conference call, and replay are open to all interested parties. Non-GAAP disclosure In addition to the Company’s financial results determined in accordance with U.S. GAAP, the Company provides non-GAAP measures that it determines to be useful in evaluating its operating performance and liquidity. The Company presents core revenue, non-GAAP gross margin, non-GAAP gross profit, adjusted EBITDA, adjusted EBITDA margin, adjusted cost of sales (exclusive of amortization of acquired intangible assets), adjusted resear